Cornerstone Capital Inc. Purchases New Holdings in Nephros Inc. $NEPH

Cornerstone Capital Inc. purchased a new stake in shares of Nephros Inc. (NASDAQ:NEPH) in the second quarter, Holdings Channel reports. The firm purchased 128,700 shares of the company’s stock, valued at approximately $459,000.

Several other hedge funds and other institutional investors have also bought and sold shares of NEPH. HighTower Advisors LLC grew its stake in Nephros by 7.2% in the 4th quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock valued at $291,000 after purchasing an additional 4,000 shares during the period. Essex Investment Management Co. LLC raised its stake in shares of Nephros by 57.1% during the 4th quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after purchasing an additional 14,162 shares during the period. Quadrature Capital Ltd purchased a new position in shares of Nephros in the 4th quarter worth about $112,000. Marshall Wace LLP purchased a new position in shares of Nephros in the 4th quarter worth about $107,000. Finally, XTX Topco Ltd grew its position in Nephros by 48.5% during the fourth quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after buying an additional 7,062 shares during the period. Hedge funds and other institutional investors own 41.10% of the company’s stock.

Nephros Price Performance

Shares of NASDAQ NEPH opened at $4.63 on Friday. Nephros Inc. has a one year low of $2.66 and a one year high of $6.42. The business’s fifty day moving average price is $3.57 and its 200-day moving average price is $3.52. The stock has a market capitalization of $50.28 million, a PE ratio of 28.94 and a beta of 1.51.

Nephros (NASDAQ:NEPH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter. Nephros had a return on equity of 10.60% and a net margin of 8.38%.The company had revenue of $6.02 million during the quarter, compared to analyst estimates of $4.99 million. As a group, equities analysts expect that Nephros Inc. will post 0.03 EPS for the current fiscal year.

Analysts Set New Price Targets

NEPH has been the topic of several research reports. Northland Securities began coverage on shares of Nephros in a research report on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective on the stock. Zacks Research raised shares of Nephros to a “hold” rating in a research report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.